Javascript must be enabled to continue!
PRAME predicting outcome in uveal melanoma
View through CrossRef
Abstract
Uveal melanoma (UM) is the most common primary intra‐ocular malignancy in adults and carries a high risk of metastatic disease, affecting approximately 50% of patients despite advances in local tumour control. PRAME (PReferentially expressed Antigen in MElanoma) has emerged as a marker for metastatic risk; however, evidence is largely derived from mRNA expression studies rather than routine immunohistochemistry (IHC). This study evaluates PRAME protein expression by IHC in a large UM cohort and examines its association with clinicopathological features and survival outcomes. A total of 403 UM cases were included. PRAME IHC was performed on tissue microarrays (TMAs) and/or whole tumour sections and scored as positive based on nuclear staining in >10% of tumour cells. Associations were assessed using chi‐square and Mann–Whitney
U
tests. Survival outcomes were analysed using Kaplan–Meier curves and Cox proportional hazards models. PRAME positivity was identified in 5% of TMA cases and 40% of whole‐section cases. On TMAs, PRAME expression was associated with worse overall survival (median 26 versus 50 months;
p
= 0.03) but not metastasis‐free survival (MFS). In contrast, whole‐section PRAME expression was strongly associated with shorter MFS (median 5 versus 20 months;
p
< 0.001) and worse overall survival (median 13 versus 52 months;
p
= 0.04). In multivariate analysis including age, American Joint Committee on Cancer stage and BAP1 status, whole‐section PRAME positivity remained an independent adverse predictor of MFS (hazard ratio = 10.5,
p
= 0.002). PRAME IHC is a clinically meaningful prognostic biomarker in UM, particularly when assessed on whole tumour sections, where it provides strong independent prognostic information.
Title: PRAME
predicting outcome in uveal melanoma
Description:
Abstract
Uveal melanoma (UM) is the most common primary intra‐ocular malignancy in adults and carries a high risk of metastatic disease, affecting approximately 50% of patients despite advances in local tumour control.
PRAME (PReferentially expressed Antigen in MElanoma) has emerged as a marker for metastatic risk; however, evidence is largely derived from mRNA expression studies rather than routine immunohistochemistry (IHC).
This study evaluates PRAME protein expression by IHC in a large UM cohort and examines its association with clinicopathological features and survival outcomes.
A total of 403 UM cases were included.
PRAME IHC was performed on tissue microarrays (TMAs) and/or whole tumour sections and scored as positive based on nuclear staining in >10% of tumour cells.
Associations were assessed using chi‐square and Mann–Whitney
U
tests.
Survival outcomes were analysed using Kaplan–Meier curves and Cox proportional hazards models.
PRAME positivity was identified in 5% of TMA cases and 40% of whole‐section cases.
On TMAs, PRAME expression was associated with worse overall survival (median 26 versus 50 months;
p
= 0.
03) but not metastasis‐free survival (MFS).
In contrast, whole‐section PRAME expression was strongly associated with shorter MFS (median 5 versus 20 months;
p
< 0.
001) and worse overall survival (median 13 versus 52 months;
p
= 0.
04).
In multivariate analysis including age, American Joint Committee on Cancer stage and BAP1 status, whole‐section PRAME positivity remained an independent adverse predictor of MFS (hazard ratio = 10.
5,
p
= 0.
002).
PRAME IHC is a clinically meaningful prognostic biomarker in UM, particularly when assessed on whole tumour sections, where it provides strong independent prognostic information.
Related Results
Prognostic Implications Of PRAME Expression Levels In Myelodysplastic Syndromes
Prognostic Implications Of PRAME Expression Levels In Myelodysplastic Syndromes
Abstract
The preferentially expressed antigen of the melanoma (PRAME) gene was first identified in melanoma tissue as a tumour-associated antigen recognized by autol...
Inhibition of PRAME Expression Causes Cell Cycle Arrest and Apoptosis In Leukemic Cells
Inhibition of PRAME Expression Causes Cell Cycle Arrest and Apoptosis In Leukemic Cells
Abstract
Abstract 1695
Introduction:
The preferentially expressed antigen of melanoma (PRAME) was originally desc...
Abstract 1502: PRAME modulates the effect of retinoids on keratinocyte differentiation and cell cycle progression in basal cell carcinoma and cutaneous squamous cell carcinoma
Abstract 1502: PRAME modulates the effect of retinoids on keratinocyte differentiation and cell cycle progression in basal cell carcinoma and cutaneous squamous cell carcinoma
Abstract
Substantial research supports the use of retinoids as prophylactics and treatments for keratinocyte carcinomas (KC). However, the practical applications of ...
MicroRNA 145 may play an important role in uveal melanoma cell growth by potentially targeting insulin receptor substrate-1
MicroRNA 145 may play an important role in uveal melanoma cell growth by potentially targeting insulin receptor substrate-1
Background
MicroRNAs (miRNAs) contribute to tumorigenesis by acting as either oncogenes or tumor suppressor genes. In this study, we investigated the role of miR-145 in...
The Utility of PRAME and Ki-67 as Prognostic Markers for Cutaneous Melanoma
The Utility of PRAME and Ki-67 as Prognostic Markers for Cutaneous Melanoma
Abstract:
Cutaneous melanoma can lead to metastasis, and it is associated with high mortality. Currently, there are no widely accepted immunohistochemistry markers for me...
PRAME immunohistochemistry distinguishes breast secondary angiosarcoma from benign and atypical vascular lesions of the breast
PRAME immunohistochemistry distinguishes breast secondary angiosarcoma from benign and atypical vascular lesions of the breast
Abstract
Objective
We examined the utility of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry (IHC) in...
Melanoma arising in extracutaneous cellular blue naevus: report of two cases with comparison to cutaneous counterparts and uveal melanoma
Melanoma arising in extracutaneous cellular blue naevus: report of two cases with comparison to cutaneous counterparts and uveal melanoma
AbstractAimsBlue naevi are benign melanocytic lesions that typically occur in the dermis. Melanoma arising in blue naevus is rare, and shows a molecular profile distinct from conve...
The use of resiquimod (RSQ) in treatment of melanoma
The use of resiquimod (RSQ) in treatment of melanoma
Melanoma is responsible for most skin cancer-related deaths, despite accounting for only 1% of all skin cancer cases. At present, surgery is considered the most promising treatment...

